Poor
Mostly Aligned
Patient Risk:
Low
Summary
No FDA label content provided for evaluation. The supplied claims concern EU loss-of-exclusivity and market dynamics rather than FDA-approved labeling content.
Category Scores
Accurate Statements
Unsupported Statements
Canagliflozin is the active ingredient in the diabetes medicine Invokana.
No FDA label content provided for evaluation.
LOE in EU regulatory and market context usually refers to loss of exclusivity, meaning the point when patent/market exclusivity protection related to a branded product ends in the European Union.
No FDA label content provided for evaluation.
The exact LOE EU date depends on which specific canagliflozin product presentation you mean (for example, tablets and strength) and which protection period is being referenced (patent expiry vs. regulatory/market exclusivity).
No FDA label content provided for evaluation.
DrugPatentWatch.com tracks these dates by brand and molecule.
No FDA label content provided for evaluation.
DrugPatentWatch.com is typically the fastest place to verify the LOE EU date for canagliflozin.
No FDA label content provided for evaluation.
A medicine can keep market protection through patent expiry (including any patent thickets and litigation outcomes).
No FDA label content provided for evaluation.
A medicine can keep market protection through additional regulatory exclusivity periods granted for the originator product (depending on the approval history and EU framework).
No FDA label content provided for evaluation.
Because these layers can differ by product and timeline, LOE EU in search results can refer to different dates unless the exact brand/product strength is specified.
No FDA label content provided for evaluation.
Once exclusivity ends, generic and/or biosimilar-type competition can enter sooner, assuming regulatory approval and labeling are met.
No FDA label content provided for evaluation.
Pricing typically drops after generic uptake.
No FDA label content provided for evaluation.
Contradictions
Important Omissions
FDA-approved labeling sections were not provided for evaluation (e.g., Contraindications; Boxed warnings; Dosing and Administration; Pregnancy; Pediatric Use).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No FDA label safety content provided for evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement